Jul 15, 2026 08:00AM
Jul 15, 2026 08:00AM
Jul 9, 2026 06:49AM
Jul 8, 2026 08:02AM
Jul 8, 2026 08:00AM
Jun 5, 2026 08:00AM
Jun 3, 2026 06:53AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Jun 2, 2026 08:00AM
Jun 2, 2026 08:00AM
May 15, 2026 08:00AM
May 15, 2026 08:00AM
May 13, 2026 08:02AM
May 13, 2026 08:00AM
May 11, 2026 07:12AM UroGen Pharma (URGN) PT Raised to $45 at H.C. Wainwright
May 6, 2026 08:00AM
Mar 30, 2026 08:05AM
Mar 30, 2026 08:00AM
Mar 6, 2026 04:10PM
Mar 2, 2026 08:04AM
Mar 2, 2026 08:00AM
Feb 27, 2026 08:30AM ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
Feb 24, 2026 04:05PM
Feb 23, 2026 08:00AM
Feb 4, 2026 08:00AM
Jan 5, 2026 08:00AM
Dec 22, 2025 07:06AM
Dec 5, 2025 08:00AM
Nov 6, 2025 08:00AM UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
Nov 6, 2025 07:58AM
Nov 6, 2025 07:58AM
Nov 4, 2025 08:00AM
Oct 30, 2025 08:00AM
Oct 27, 2025 08:00AM
Oct 24, 2025 08:29AM
Oct 2, 2025 08:02AM UroGen publishes clinical review of ZUSDURI for bladder cancer treatment
Oct 2, 2025 08:00AM
Sep 8, 2025 08:00AM
Aug 21, 2025 08:00AM
Aug 19, 2025 06:18AM
Aug 7, 2025 08:00AM
Aug 5, 2025 08:00AM
Aug 5, 2025 08:00AM UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscl
Jul 29, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 21, 2025 08:05AM
Jul 21, 2025 08:00AM
Jul 8, 2025 06:50AM
Jul 7, 2025 08:04AM UroGen completes enrollment in phase 3 bladder cancer drug trial
Jul 7, 2025 08:00AM

325,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All